Long‐term outcome of high‐grade encapsulated papillary carcinoma of the breast: implications for staging and management

BACKGROUND: Encapsulated papillary carcinoma (EPC) of the breast is an uncommon tumour with controversial biological behaviour and staging. Emerging evidence suggests that EPC with adverse pathological features (EPC-A) may exhibit invasive potential. The absence of uniform staging criteria contributes to management variability. This study evaluates the clinicopathological characteristics and clinical course of high-grade EPC (HG-EPC), including EPC-A. MATERIALS AND METHODS: This retrospective multicentre study (2000-2025) included 25 HG-EPC cases, irrespectively of ER/PR and HER2 status. Tumours with frank stromal invasion beyond microinvasive foci were excluded. Histopathological re-evaluation was performed in accordance with 2019 WHO classification criteria. RESULTS: Of 38 cases reviewed, 25 fulfilled the inclusion criteria as EPC (mean age 57.2 years, mean tumour size 2.9 cm). Six cases (24%) demonstrated conventional-type microinvasive components. A subset of 16 cases fulfilled criteria for EPC-A, defined by high-grade morphology in combination with ER/PR-negative (or ER <30% positive) and/or HER2-positive status. Staging and management were variable. Initial pathological stage varied: pTis (n = 13) to pT1 (n = 4) or pT2 (n = 7), and pT3 (n = 1). Adjuvant chemotherapy and radiotherapy were administered in 7 and 12 patients respectively. During follow-up, four local recurrences (three invasive and one in situ) were observed. One of the locally recurrent patients subsequently developed distant metastasis, and one breast cancer-related death occurred 200 months after diagnosis. Recurrence or death occurred in 20% (5/25) of patients despite therapy. Microinvasion was seen only in the EPC-A tumours. CONCLUSION: HG-EPC and EPC-A overlap morphologically and diagnostically with frankly invasive carcinomas and demonstrate a non-negligible risk of recurrence. Clinical outcomes and more frequent microinvasion in EPC-A support the view that EPC-A is more appropriately regarded as an indolent form of invasive carcinoma rather than a purely in situ lesion and demonstrate a non-negligible risk of recurrence and highlight the need for standardized staging criteria.

Authors

Institutions

Publication Details

Journal
Histopathology
Published
2026-08-03
DOI
https://doi.org/10.1111/his.70240
Primary Topic
Breast Lesions and Carcinomas
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Long‐term outcome of high‐grade encapsulated papillary carcinoma of the breast: implications for staging and management

Umberto Macciò, Bärbel Papassotiropoulos, Zsuzsanna Varga, Emad A. Rakha et al.
Histopathology
Breast Lesions and Carcinomas
article

Long‐term outcome of high‐grade encapsulated papillary carcinoma of the breast: implications for staging and management

Umberto Macciò, Bärbel Papassotiropoulos, Zsuzsanna Varga, Emad A. Rakha, Isabell Witzel, Heike Frauchiger-Heuer, Lidija Stevanovic, Hisham Fansa, Ian O. Ellis, Milena Stevanovic
article en

Abstract

BACKGROUND: Encapsulated papillary carcinoma (EPC) of the breast is an uncommon tumour with controversial biological behaviour and staging. Emerging evidence suggests that EPC with adverse pathological features (EPC-A) may exhibit invasive potential. The absence of uniform staging criteria contributes to management variability. This study evaluates the clinicopathological characteristics and clinical course of high-grade EPC (HG-EPC), including EPC-A. MATERIALS AND METHODS: This retrospective multicentre study (2000-2025) included 25 HG-EPC cases, irrespectively of ER/PR and HER2 status. Tumours with frank stromal invasion beyond microinvasive foci were excluded. Histopathological re-evaluation was performed in accordance with 2019 WHO classification criteria. RESULTS: Of 38 cases reviewed, 25 fulfilled the inclusion criteria as EPC (mean age 57.2 years, mean tumour size 2.9 cm). Six cases (24%) demonstrated conventional-type microinvasive components. A subset of 16 cases fulfilled criteria for EPC-A, defined by high-grade morphology in combination with ER/PR-negative (or ER <30% positive) and/or HER2-positive status. Staging and management were variable. Initial pathological stage varied: pTis (n = 13) to pT1 (n = 4) or pT2 (n = 7), and pT3 (n = 1). Adjuvant chemotherapy and radiotherapy were administered in 7 and 12 patients respectively. During follow-up, four local recurrences (three invasive and one in situ) were observed. One of the locally recurrent patients subsequently developed distant metastasis, and one breast cancer-related death occurred 200 months after diagnosis. Recurrence or death occurred in 20% (5/25) of patients despite therapy. Microinvasion was seen only in the EPC-A tumours. CONCLUSION: HG-EPC and EPC-A overlap morphologically and diagnostically with frankly invasive carcinomas and demonstrate a non-negligible risk of recurrence. Clinical outcomes and more frequent microinvasion in EPC-A support the view that EPC-A is more appropriately regarded as an indolent form of invasive carcinoma rather than a purely in situ lesion and demonstrate a non-negligible risk of recurrence and highlight the need for standardized staging criteria.

Histopathology
Nottingham University Hospitals NHS Trust (GB), University of Nottingham (GB), University of Zurich (CH), University Hospital of Zurich (CH), Breast Center (CH), Spital Zollikerberg (CH)
Openalex Percentile: Top 10%
Breast Lesions and Carcinomas
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.